SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Emergent BioSolutions Inc. (EBS) trades at a trailing P/E of 8.5, forward P/E of 16.7. Trailing earnings yield is 11.83%, forward earnings yield 6.01%. PEG 0.83 (Peter Lynch undervalued ≤1.0). Graham Number is $14.70.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (8.5); PEG ≤ 1.0 — Peter Lynch undervalued (0.83); analyst target implies upside (+494.7%); earnings yield beats bond yields (11.83%).
- PEG Ratio 0.83 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 11.83% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $51.50 (+494.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EBS
Valuation Multiples
P/E (TTM)8.5
Forward P/E16.7
PEG Ratio0.83
Forward PEG0.83
P/B Ratio0.85
P/S Ratio0.58
EV/EBITDA3.9
Per Share Data
EPS (TTM)$0.98
Forward EPS (Est.)$0.52
Book Value / Share$9.77
Revenue / Share$13.89
FCF / Share$2.93
Yields & Fair Value
Earnings Yield11.83%
Forward Earnings Yield6.01%
Dividend Yield0.00%
Graham Number$14.70
SharesGrow IV$4.16 (-52%)
Analyst Target$51.50 (+494.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
25.5 |
-1.22 |
2.21 |
2.70 |
- |
| 2017 |
23.5 |
0.44 |
2.13 |
3.46 |
- |
| 2018 |
47.4 |
-1.28 |
2.94 |
3.80 |
- |
| 2019 |
51.0 |
-3.35 |
2.55 |
2.51 |
- |
| 2020 |
15.4 |
0.03 |
3.26 |
2.99 |
- |
| 2021 |
10.6 |
-0.36 |
1.44 |
1.31 |
- |
| 2022 |
-2.8 |
0.01 |
0.43 |
0.53 |
- |
| 2023 |
-0.2 |
0.00 |
0.19 |
0.12 |
- |
| 2024 |
-2.7 |
0.04 |
1.05 |
0.49 |
- |
| 2025 |
12.6 |
-0.10 |
1.27 |
0.89 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.13 |
$488.78M |
$51.78M |
10.6% |
| 2017 |
$1.71 |
$560.87M |
$82.59M |
14.7% |
| 2018 |
$1.22 |
$782.4M |
$62.7M |
8% |
| 2019 |
$1.04 |
$1.11B |
$54.5M |
4.9% |
| 2020 |
$5.67 |
$1.56B |
$305.8M |
19.7% |
| 2021 |
$4.06 |
$1.79B |
$219.5M |
12.2% |
| 2022 |
$-4.47 |
$1.12B |
$-223.8M |
-20% |
| 2023 |
$-14.85 |
$1.05B |
$-760.5M |
-72.5% |
| 2024 |
$-3.60 |
$1.01B |
$-190.6M |
-18.8% |
| 2025 |
$0.93 |
$742.9M |
$52.6M |
7.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.52 |
$0.52 – $0.52 |
$745M |
$743.67M – $746.33M |
1 |
| 2027 |
$-0.96 |
$-0.96 – $-0.96 |
$892M |
$890.41M – $893.59M |
1 |
| 2028 |
$0.43 |
$0.43 – $0.43 |
$878.6M |
$877.03M – $880.17M |
1 |
| 2029 |
$0.90 |
$0.90 – $0.90 |
$963.2M |
$961.48M – $964.92M |
1 |
